Skip to main content
  • Novel Drug-Eluting Scaffold Noninferior to Commercial DES for TLF, Shows Better Restored Vessel Function at 1 Year

    A novel drug-eluting scaffold was noninferior to a commercially available current-generation drug-eluting stent (DES) in terms of target lesion failure (TLF) and improved restoration of vessel motion and function at 1 year, according to new randomized trial results.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details